---
title: "Madrigal Pharmaceuticals (MDGL) Gets a Buy from UBS"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293390160.md"
description: "UBS analyst Ashwani Verma maintained a Buy rating on Madrigal Pharmaceuticals (MDGL) with a $669 price target. This follows a Buy from Citizens JMP and contrasts with Bank of America's Hold rating."
datetime: "2026-07-21T21:49:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293390160.md)
  - [en](https://longbridge.com/en/news/293390160.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293390160.md)
generator: "portal-rs"
---

# Madrigal Pharmaceuticals (MDGL) Gets a Buy from UBS

In a report released today, Ashwani Verma from UBS maintained a Buy rating on Madrigal Pharmaceuticals, with a price target of $669.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Verma is a 4-star analyst with an average return of 13.5% and a 60.93% success rate. Verma covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Incyte, and Insmed.

In addition to UBS, Madrigal Pharmaceuticals also received a Buy from Citizens JMP’s Jonathan Wolleben in a report issued on July 17. However, on July 13, Bank of America Securities reiterated a Hold rating on Madrigal Pharmaceuticals (NASDAQ: MDGL).

### Related Stocks

- [MDGL.US](https://longbridge.com/en/quote/MDGL.US.md)
- [UBS.US](https://longbridge.com/en/quote/UBS.US.md)
- [JAZZ.US](https://longbridge.com/en/quote/JAZZ.US.md)
- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)

## Related News & Research

- [Can Madrigal Pharmaceuticals (MDGL) Still Offer Value After Its Big Run?](https://longbridge.com/en/news/297367016.md)
- [How Investors May Respond To Madrigal (MDGL) Adding J&J R&D Leader John C. Reed To Its Board](https://longbridge.com/en/news/296565323.md)
- [ANI Pharma CEO Nikhil Lalwani disposes of 5,400 common shares worth $401,220](https://longbridge.com/en/news/297093829.md)
- [Madrigal Pharma director John C. Reed files initial beneficial ownership statement](https://longbridge.com/en/news/296270622.md)
- [Madrigal grants 4,676 inducement RSUs to 13 new employees under 2025 plan](https://longbridge.com/en/news/296530865.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**